Hormonal
GLP-1 receptor agonists (GLP-1RAs) treat obesity by activating central and peripheral GLP-1 receptors to increase satiety, delay gastric emptying, and modulate energy expenditure, resulting in significant weight loss.
GLP-1 receptor agonists are a class of medications that mimic a gut hormone to signal fullness to the brain and slow digestion. They are prescribed for obesity and type 2 diabetes. Common examples include Semaglutide (Ozempic/Wegovy) and Liraglutide (Saxenda). These drugs require a prescription and often involve starting at a low dose to manage side effects like nausea. They are part of a long-term management strategy for obesity, not a quick fix.
GLP-1R agonists have a hypoglycemic effect second only to insulin and have the advantages of low risk of hypoglycemia, significant weight loss effect, and cardiovascular benefits... GLP-1 from the gut can also transmit information upward to the central nervous system via the vagus nerve, which in turn inhibits vagus activity and stomach emptying, increasing satiety.
Why this rating
The paper reviews multiple approved drugs (Semaglutide, Liraglutide, Tirzepatide) with clinical trial data, though it is a review rather than a single primary RCT.
Source
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Jiahua Zhang et al. · International Journal of Molecular Sciences · 2025
DOI 10.3390/ijms26041651
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →